Journal of Shanghai University >
Circulating miR-21-3p as biomarkers for sepsis-induced cardiomyopathy
Received date: 2016-04-22
Online published: 2016-06-30
Recently, microRNAs(miRNAs) are found to be abundantly present in body fluids including plasma and serum, and called circulating miRNAs. Increasing evidences suggest that circulating miRNAs may be useful as stable blood-based biomarkers in sepsis. Serum miR-21-3p is significantly increased in septic patients compared with healthy controls. Receiver operating characteristic (ROC) curve analyses suggest that these plasma miR-21-3p may be useful biomarkers for discriminating patients with sepsis-induced cardiomyopathy (SIC) from healthy controls. miR-21-3p yields the ROC area under the curve
(AUC) of 0.949. Further analyses indicate that the expression level of miR-21-3p is correlated with the brain natriuretic peptide (BNP) (r = 0.968, P < 0.001) and cardiac troponin T (cTNT) level (r = 0.257, P = 0.002). Serum miR-21-3p may serve as new biomarkers for sepsis with high specificity and sensitivity.
LIU Hui, WANG Hui, SHI Jing, KONG Xiangqing . Circulating miR-21-3p as biomarkers for sepsis-induced cardiomyopathy[J]. Journal of Shanghai University, 2016 , 22(3) : 366 -370 . DOI: 10.3969/j.issn.1007-2861.2016.03.019
[1] Bone R C, Balk R A, Cerra F B, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis [J]. Chest, 1992, 101(6): 1644-1655.
[2] Bone R C. Gram-negative sepsis. Background, clinical features, and intervention [J]. Chest, 1991, 100(3): 802-808.
[3] Martin G S, Mannino D M, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000 [J]. New England Journal of Medicine, 2003, 348(16): 1546-1554.
[4] Merx M W, Weber C. Sepsis and the heart [J]. Circulation, 2007, 116(7): 793-802.
[5] Zaky A, Deem S, Bendjelid K, et al. Characterization of cardiac dysfunction in sepsis: an ongoing challenge [J]. Shock, 2014, 41(1): 12-24.
[6] Angus D C, Linde-Zwirble W T, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care [J]. Critical Care
Medicine, 2001, 29(7): 1303-1310.
[7] Annane D, Bellissant E, Cavaillon J M. Septic shock [J]. Lancet, 2005, 365(9453): 63-78.
[8] Wang J F, Yu M L, Yu G, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis [J]. Biochemical and Biophysical Research Communications, 2010, 394(1): 184-188.
[9] Wang L, Wang H C, Chen C, et al. Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients [J]. Experimental and Therapeutic Medicine, 2013, 5(4): 1101-1104.
[10] Roderburg C, Luedde M, Vargas C D, et al. Circulating microRNA-150 serum levels predict survival in patients with critical illness and sepsis [J]. PLoS One, 2013, 8(1): e54612.
[11] Wu S C, Yang J C, Rau C S, et al. Profiling circulating microRNA expression in experimental sepsis using cecal ligation and puncture [J]. PLoS One, 2013, 8(1): e77936.
[12] Wang H, Zhang P, Chen W, et al. Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects [J]. Clinical Chemistry and Laboratory Medicine, 2012, 50(8): 1423-1428.
[13] Tacke F, Roderburg C, Benz F, et al. Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients [J]. Critical Care Medicine, 2014, 42(5): 1096-1104.
[14] Wang H, Meng K, Chen W, et al. Serum miR-574-5p: a prognostic predictor of sepsis patients [J]. Shock, 2012, 37(3): 263-267.
[15] Wang H, Bei Y, Shen S, et al. miR-21-3p controls sepsis-associated cardiac dysfunction via regulating SORBS2 [J]. Journal of Molecular and Cellular Cardiology, 2016, 94: 43-53.
/
| 〈 |
|
〉 |
